TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Carotid Plaque Screening on Smoking Cessation and Control of Other Cardiovascular Risk Factors: A Randomized Controlled Trial.
Brief Summary: The purpose of this study is to determine the impact of carotid plaque screening on smoking cessation and control of other cardiovascular risk factors.


Options:
A: Arm Label: Spirometry and a brief advice to quit smoking; Type: EXPERIMENTAL; Interventions: Behavioral: Spirometry and a brief advice to quit smoking | Arm Label: Brief advice to quit smoking; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief advice to quit smoking | Intervention Type: BEHAVIORAL; Name: Spirometry and a brief advice to quit smoking; Assigned to Arm(s): Spirometry and a brief advice to quit smoking | Intervention Type: BEHAVIORAL; Name: Brief advice to quit smoking; Assigned to Arm(s): Brief advice to quit smoking
B: Arm Label: Usual care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: Lung Age; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lung age | Arm Label: Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Contingency Management | Arm Label: Lung age + Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lung age + Contingency Management | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual care | Intervention Type: BEHAVIORAL; Name: Lung age; Assigned to Arm(s): Lung Age | Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): Contingency Management | Intervention Type: BEHAVIORAL; Name: Lung age + Contingency Management; Assigned to Arm(s): Lung age + Contingency Management
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Carotid ultrasound for plaque screening, Behavioral: Brief advice for smoking cessation | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief advice for smoking cessation | Intervention Type: DEVICE; Name: Carotid ultrasound for plaque screening; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Brief advice for smoking cessation; Assigned to Arm(s): 1, 2
D: Arm Label: CO reminder; Type: EXPERIMENTAL; Interventions: Behavioral: Informing surgical patients about CO monitoring | Arm Label: no CO reminder; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: a brief intervention recommending preoperative abstinence from smoking | Intervention Type: BEHAVIORAL; Name: Informing surgical patients about CO monitoring; Assigned to Arm(s): CO reminder | Intervention Type: BEHAVIORAL; Name: a brief intervention recommending preoperative abstinence from smoking; Assigned to Arm(s): no CO reminder

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Prospective Randomized Trial Comparing Radiosurgery With Versus Without Whole Brain Radiotherapy for 1-3 Newly Diagnosed Brain Metastases
Brief Summary: The goal of this clinical research study is to learn if your thinking ability (cognitive function) will be better preserved by delivering whole brain radiation therapy immediately after radiosurgical treatment of 1-3 brain metastases or to carefully observe patients after radiosurgery and hold back whole brain radiation therapy until the disease comes back.


Options:
A: Arm Label: WBRT with Hippocampal Avoidance; Type: OTHER; Interventions: Radiation: intensity-modulated radiation therapy | Intervention Type: RADIATION; Name: intensity-modulated radiation therapy; Assigned to Arm(s): WBRT with Hippocampal Avoidance
B: Arm Label: ketogenic diet and transient fasting; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calorie-restricted ketogenic diet and transient fasting | Arm Label: standard nutrition; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: standard nutrition | Intervention Type: DIETARY_SUPPLEMENT; Name: calorie-restricted ketogenic diet and transient fasting; Assigned to Arm(s): ketogenic diet and transient fasting | Intervention Type: DIETARY_SUPPLEMENT; Name: standard nutrition; Assigned to Arm(s): standard nutrition
C: Arm Label: Brain Training; Type: EXPERIMENTAL; Interventions: Behavioral: Brain Training Program | Arm Label: Brain Health; Type: EXPERIMENTAL; Interventions: Behavioral: Brain Health Program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Brain Training Program; Assigned to Arm(s): Brain Training | Intervention Type: BEHAVIORAL; Name: Brain Health Program; Assigned to Arm(s): Brain Health
D: Arm Label: Whole Brain Radiation Therapy; Type: EXPERIMENTAL; Interventions: Procedure: Whole Brain Radiation Therapy, Behavioral: Questionnaire | Arm Label: Observation; Type: OTHER; Interventions: Other: Observation, Behavioral: Questionnaire | Intervention Type: PROCEDURE; Name: Whole Brain Radiation Therapy; Assigned to Arm(s): Whole Brain Radiation Therapy | Intervention Type: OTHER; Name: Observation; Assigned to Arm(s): Observation | Intervention Type: BEHAVIORAL; Name: Questionnaire; Assigned to Arm(s): Observation, Whole Brain Radiation Therapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of CDP870 400 mg Subcutaneously Versus Placebo in the Treatment of the Signs and Symptoms of Patients With Rheumatoid Arthritis Who Have Previously Failed at Least One DMARD
Brief Summary: The purpose of this study was to confirm and extend the data from previous studies and to demonstrate the efficacy (in terms of signs and symptoms) and safety of monotherapy with CDP870 administered SC every 4 weeks compared to placebo in patients with active RA who had failed at least one DMARD.


Options:
A: Arm Label: TNF-blocking drug; Type: EXPERIMENTAL; Interventions: Drug: Etanercept, Drug: Adalimumab, Drug: Certolizumab Pegol, Drug: Infliximab, Drug: Golimumab | Arm Label: Abatacept; Type: EXPERIMENTAL; Interventions: Drug: Abatacept | Arm Label: Rituximab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Rituximab | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): TNF-blocking drug | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept | Intervention Type: BIOLOGICAL; Name: Rituximab; Assigned to Arm(s): Rituximab | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): TNF-blocking drug | Intervention Type: DRUG; Name: Certolizumab Pegol; Assigned to Arm(s): TNF-blocking drug | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): TNF-blocking drug | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): TNF-blocking drug
B: Arm Label: Certolizumab pegol (CZP); Type: EXPERIMENTAL; Interventions: Drug: Certolizumab pegol (CZP) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Certolizumab pegol (CZP); Assigned to Arm(s): Certolizumab pegol (CZP) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Cimzia; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab pegol | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): Cimzia

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of CDP870 400 mg Subcutaneously Versus Placebo in the Treatment of the Signs and Symptoms of Patients With Rheumatoid Arthritis Who Have Previously Failed at Least One DMARD
Brief Summary: The purpose of this study was to confirm and extend the data from previous studies and to demonstrate the efficacy (in terms of signs and symptoms) and safety of monotherapy with CDP870 administered SC every 4 weeks compared to placebo in patients with active RA who had failed at least one DMARD.


Options:
A: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A
B: Arm Label: Golimumab (CNTO 148) with Methotrexate (MTX); Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: MTX | Arm Label: Infliximab with MTX; Type: EXPERIMENTAL; Interventions: Drug: MTX, Drug: Infliximab | Arm Label: Placebo with MTX; Type: PLACEBO_COMPARATOR; Interventions: Drug: MTX, Drug: Placebo | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Golimumab (CNTO 148) with Methotrexate (MTX) | Intervention Type: DRUG; Name: MTX; Assigned to Arm(s): Golimumab (CNTO 148) with Methotrexate (MTX), Infliximab with MTX, Placebo with MTX | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo with MTX | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): Infliximab with MTX
C: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: methotrexate, Drug: Placebo, triple | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: Sulfasalazine, Drug: Hydroxychloroquine, Drug: Placebo, etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: Sulfasalazine; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Hydroxychloroquine; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Placebo, triple; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Placebo, etanercept; Assigned to Arm(s): Arm 2
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept , Methotrexate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide | Intervention Type: DRUG; Name: Etanercept , Methotrexate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of CDP870 400 mg Subcutaneously Versus Placebo in the Treatment of the Signs and Symptoms of Patients With Rheumatoid Arthritis Who Have Previously Failed at Least One DMARD
Brief Summary: The purpose of this study was to confirm and extend the data from previous studies and to demonstrate the efficacy (in terms of signs and symptoms) and safety of monotherapy with CDP870 administered SC every 4 weeks compared to placebo in patients with active RA who had failed at least one DMARD.


Options:
A: Arm Label: MabThera/Rituxan; Type: EXPERIMENTAL; Interventions: Drug: methotrexate, Drug: rituximab [MabThera/Rituxan] | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): MabThera/Rituxan | Intervention Type: DRUG; Name: rituximab [MabThera/Rituxan]; Assigned to Arm(s): MabThera/Rituxan
B: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A
C: Arm Label: Certolizumab Pegol; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol; Assigned to Arm(s): Certolizumab Pegol
D: Arm Label: 1a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 1b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate, Drug: Placebo | Arm Label: 2a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate, Drug: Placebo | Arm Label: 2b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1a, 1b, 2a | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1a, 1b, 2a, 2b | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1b, 2a

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of CDP870 400 mg Subcutaneously Versus Placebo in the Treatment of the Signs and Symptoms of Patients With Rheumatoid Arthritis Who Have Previously Failed at Least One DMARD
Brief Summary: The purpose of this study was to confirm and extend the data from previous studies and to demonstrate the efficacy (in terms of signs and symptoms) and safety of monotherapy with CDP870 administered SC every 4 weeks compared to placebo in patients with active RA who had failed at least one DMARD.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3
B: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A
C: Arm Label: 1a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 1b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate, Drug: Placebo | Arm Label: 2a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate, Drug: Placebo | Arm Label: 2b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1a, 1b, 2a | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1a, 1b, 2a, 2b | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1b, 2a
D: Arm Label: Group 1: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Biological: Golimumab 50 mg | Arm Label: Group 2: Golimumab 50 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 50 mg | Arm Label: Group 3: Golimumab 100 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1: Placebo | Intervention Type: BIOLOGICAL; Name: Golimumab 50 mg; Assigned to Arm(s): Group 1: Placebo, Group 2: Golimumab 50 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 100 mg; Assigned to Arm(s): Group 3: Golimumab 100 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of CDP870 400 mg Subcutaneously Versus Placebo in the Treatment of the Signs and Symptoms of Patients With Rheumatoid Arthritis Who Have Previously Failed at Least One DMARD
Brief Summary: The purpose of this study was to confirm and extend the data from previous studies and to demonstrate the efficacy (in terms of signs and symptoms) and safety of monotherapy with CDP870 administered SC every 4 weeks compared to placebo in patients with active RA who had failed at least one DMARD.


Options:
A: Arm Label: Group I: Placebo + Methotrexate (MTX); Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Other: Placebo, Drug: methotrexate (MTX) | Arm Label: Group II: Golimumab + Methotrexate (MTX); Type: PLACEBO_COMPARATOR; Interventions: Drug: Golimumab, Other: Placebo, Drug: methotrexate (MTX) | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Group I: Placebo + Methotrexate (MTX), Group II: Golimumab + Methotrexate (MTX) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group I: Placebo + Methotrexate (MTX), Group II: Golimumab + Methotrexate (MTX) | Intervention Type: DRUG; Name: methotrexate (MTX); Assigned to Arm(s): Group I: Placebo + Methotrexate (MTX), Group II: Golimumab + Methotrexate (MTX)
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept , Methotrexate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide | Intervention Type: DRUG; Name: Etanercept , Methotrexate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A
D: Arm Label: Rituximab (0.5 g x 2) + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: folate, Drug: methotrexate, Drug: methylprednisolone, Drug: rituximab | Arm Label: Rituximab (1.0 g x 2) + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: folate, Drug: methotrexate, Drug: methylprednisolone, Drug: rituximab | Arm Label: Placebo + Methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: folate, Drug: methotrexate, Drug: methylprednisolone, Drug: placebo | Intervention Type: DRUG; Name: folate; Assigned to Arm(s): Placebo + Methotrexate, Rituximab (0.5 g x 2) + Methotrexate, Rituximab (1.0 g x 2) + Methotrexate | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): Placebo + Methotrexate, Rituximab (0.5 g x 2) + Methotrexate, Rituximab (1.0 g x 2) + Methotrexate | Intervention Type: DRUG; Name: methylprednisolone; Assigned to Arm(s): Placebo + Methotrexate, Rituximab (0.5 g x 2) + Methotrexate, Rituximab (1.0 g x 2) + Methotrexate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo + Methotrexate | Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): Rituximab (0.5 g x 2) + Methotrexate, Rituximab (1.0 g x 2) + Methotrexate

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of CDP870 400 mg Subcutaneously Versus Placebo in the Treatment of the Signs and Symptoms of Patients With Rheumatoid Arthritis Who Have Previously Failed at Least One DMARD
Brief Summary: The purpose of this study was to confirm and extend the data from previous studies and to demonstrate the efficacy (in terms of signs and symptoms) and safety of monotherapy with CDP870 administered SC every 4 weeks compared to placebo in patients with active RA who had failed at least one DMARD.


Options:
A: Arm Label: CP-690,550 + methotrexate; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 + methotrexate | Arm Label: Placebo + methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + Methotrexate | Intervention Type: DRUG; Name: CP-690,550 + methotrexate; Assigned to Arm(s): CP-690,550 + methotrexate | Intervention Type: DRUG; Name: Placebo + Methotrexate; Assigned to Arm(s): Placebo + methotrexate
B: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A
C: Arm Label: Certolizumab pegol 400 mg and placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Certolizumab pegol, Other: Placebo | Arm Label: Certolizumab pegol 200 mg and placebo; Type: EXPERIMENTAL; Interventions: Drug: Certolizumab pegol, Other: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 400 mg and placebo | Intervention Type: DRUG; Name: Certolizumab pegol; Assigned to Arm(s): Certolizumab pegol 200 mg and placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Certolizumab pegol 200 mg and placebo, Certolizumab pegol 400 mg and placebo, Placebo
D: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Cost Effectiveness of Malaria Diagnosis Procedures and the Rational Use of ACT in Zanzibar
Brief Summary: The purpose of this study is to assess performance and cost-effectiveness of rapid diagnostic test(RDT) aided malaria diagnosis versus symptom-based/clinical diagnosis in patients of all ages with reported fever last 48 hours alone in primary health care settings in Zanzibar.


Options:
A: Intervention Type: DEVICE; Name: Rapid diagnostic test for malaria; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Rapid diagnostic test for malaria | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Rapid diagnostic test for malaria | Intervention Type: DEVICE; Name: Rapid diagnostic test for malaria; Assigned to Arm(s): 1, 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Coartem and amoxicillin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Coartem | Intervention Type: DRUG; Name: Coartem and amoxicillin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Coartem; Assigned to Arm(s): 2
D: Intervention Type: DEVICE; Name: Rapid Diagnostic Test for P. falciparum malaria; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Cost Effectiveness of Malaria Diagnosis Procedures and the Rational Use of ACT in Zanzibar
Brief Summary: The purpose of this study is to assess performance and cost-effectiveness of rapid diagnostic test(RDT) aided malaria diagnosis versus symptom-based/clinical diagnosis in patients of all ages with reported fever last 48 hours alone in primary health care settings in Zanzibar.


Options:
A: Intervention Type: DEVICE; Name: Rapid Diagnostic Test for P. falciparum malaria; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo | Intervention Type: DRUG; Name: Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo; Assigned to Arm(s): 1, 2, 3
C: Intervention Type: DEVICE; Name: Rapid diagnostic test for malaria; Assigned to Arm(s): N/A
D: Arm Label: RDT+ACT group; Type: EXPERIMENTAL; Interventions: Device: RDT, Other: Clinical Judgement as basis for treatment of malaria with ACT | Arm Label: Clinical judgement+ACT group; Type: ACTIVE_COMPARATOR; Interventions: Device: RDT, Other: Clinical Judgement as basis for treatment of malaria with ACT | Intervention Type: DEVICE; Name: RDT; Assigned to Arm(s): Clinical judgement+ACT group, RDT+ACT group | Intervention Type: OTHER; Name: Clinical Judgement as basis for treatment of malaria with ACT; Assigned to Arm(s): Clinical judgement+ACT group, RDT+ACT group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Variable-Dose Titration Followed by a Randomized Double-Blind Study of Controlled-Release OROS® Hydromorphone HCl (NMED-1077) Compared to Placebo in Patients With Chronic Low Back Pain
Brief Summary: This study will test an experimental drug called OROS® hydromorphone hydrochloride (HCl) (NMED-1077), a once daily opioid analgesic that can relieve pain. A large number of clinical studies have been conducted to test this drug. OROS hydromorphone HCl is currently approved in both the US and Europe to treat chronic pain.

The purpose of this study is to compare OROS hydromorphone to placebo to see if it is safe and efficacious.


Options:
A: Arm Label: OROS hydromorphone; Type: EXPERIMENTAL; Interventions: Drug: OROS hydromorphone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: OROS hydromorphone; Assigned to Arm(s): OROS hydromorphone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Intervention Type: DRUG; Name: OROS Hydromorphone HCI; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: CG 5503;tapentadol; Assigned to Arm(s): N/A
D: Arm Label: Double-blind BTDS 10 or 20; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine transdermal system | Arm Label: Double-blind Placebo TDS; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Buprenorphine transdermal system; Assigned to Arm(s): Double-blind BTDS 10 or 20 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Double-blind Placebo TDS

Answer: A